הכנסה תפעולית לפני ניכוי פחת: Karuna Therapeutics Inc (KRTX)

Absolute profit from core operations demonstrates the potential of Cobenfy following the deal with the industry behemoth and expansion into Alzheimer's therapy. reflects the latest metric value, highlighting liquidity that offsets R&D costs. However, the curve's volatility correlates with patent disputes and costly promotional campaigns for new psychotropic drugs, creating certain financial risks for Karuna Therapeutics (KRTX).

To filter blue-chip assets, investors assess the real scale of a business via operating cash flow before interest and taxes. This metric measures the fundamental strength of an enterprise, which, in the case of the monopoly status of the drug Cobenfy from Karuna Therapeutics (KRTX), converts into predictable profit growth, as clearly reflected by the upward trend in absolute EBITDA.